# EDGAR Filing Document

**Accession Number:** 0001139685
**File Stem:** 0001213900-26-025764
**Filing Date:** 2026-3
**Character Count:** 6115
**Document Hash:** 918e8f068cf1784cbc779b434e6b914d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001213900-26-025764.hdr.sgml**: 20260310

**ACCESSION NUMBER**: 0001213900-26-025764

**CONFORMED SUBMISSION TYPE**: SCHEDULE 13D

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20260310

**DATE AS OF CHANGE**: 20260310

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** 20/20 Biolabs, Inc.
- **CENTRAL INDEX KEY:** 0001139685
- **STANDARD INDUSTRIAL CLASSIFICATION:** SERVICES-TESTING LABORATORIES [8734]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 522272107
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-95532
- **FILM NUMBER:** 26740463

**BUSINESS ADDRESS:**
- **STREET 1:** 9430 KEY WEST AVENUE
- **STREET 2:** SUITE 100
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** 2404536339

**MAIL ADDRESS:**
- **STREET 1:** 15810 GAITHER ROAD, SUITE 235
- **STREET 2:** SUITE 235
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20877

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 20/20 GeneSystems, Inc.
- **DATE OF NAME CHANGE:** 20150922

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** 20/20 GENE SYSTEMS INC
- **DATE OF NAME CHANGE:** 20010502
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Cohen Jonathan M
- **CENTRAL INDEX KEY:** 0002111543

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** SCHEDULE 13D

**MAIL ADDRESS:**
- **STREET 1:** 5810 GAITHER ROAD
- **STREET 2:** SUITE 235
- **CITY:** GAITHERSBURG
- **STATE:** MD
- **ZIP:** 20877

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## SCHEDULE 13D

### Under the Securities Exchange Act of 1934

**20/20 Biolabs, Inc.**

*(Name of Issuer)*

**Common Stock, par value $0.01**

*(Title of Class of Securities)*

**90138K101**

*(CUSIP Number)*

**Jonathan Cohen**<br>c/o 20/20 Biolabs, Inc.<br>15810 Gaither Road, Suite 235<br>Gaithersburg MD 20877<br>240-453-6339

*(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)*

**03/03/2026**

*(Date of Event Which Requires Filing of this Statement)*

| **CUSIP No.** | **90138K101** |

---

| | | | |
|:--|:--|:--|:--|
| 1 | Name of reporting person<br>**Jonathan M Cohen** | Name of reporting person<br>**Jonathan M Cohen** | |
| 2 | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | Check the appropriate box if a member of a Group (See Instructions)<br>[x] (a)<br>[ ] (b) | |
| 3 | SEC use only | SEC use only | |
| 4 | Source of funds (See Instructions)<br>**OO** | Source of funds (See Instructions)<br>**OO** | |
| 5 | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)<br>[ ] | |
| 6 | Citizenship or place of organization<br>**X1** | Citizenship or place of organization<br>**X1** | |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 7 | Sole Voting Power<br>**1833750.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 8 | Shared Voting Power<br>**0.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 9 | Sole Dispositive Power<br>**1833750.00** |
| Number of Shares<br>Beneficially Owned by<br>Each Reporting Person With: | 10 | Shared Dispositive Power<br>**0.00** |
| 11 | Aggregate amount beneficially owned by each reporting person<br>**1833750.00** | Aggregate amount beneficially owned by each reporting person<br>**1833750.00** | |
| 12 | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)<br>[ ] | |
| 13 | Percent of class represented by amount in Row (11)<br>**16.8%** | Percent of class represented by amount in Row (11)<br>**16.8%** | |
| 14 | Type of Reporting Person (See Instructions)<br>**IN** | Type of Reporting Person (See Instructions)<br>**IN** | |

---

**Comment for Reporting Person:** The number of shares above includes 1,366,400 shares of common stock and 467,350 shares of common stock that the Reporting Person has the right to acquire within sixty (60) days through the exercise of vested stock options. The response to Row 13 above is based on 10,442,438 shares of common stock of the Issuer outstanding as of March 3, 2026.

**Item 1. Security and Issuer**

**(a) Title of Class of Securities:**
Common Stock, par value $0.01

**(b) Name of Issuer:**
20/20 Biolabs, Inc.

**(c) Address of Issuer's Principal Executive Offices:**
15810 Gaither Road, Suite 235, Gaithersburg, MD, 20877

**Item 4. Purpose of Transaction**

The securities held by the Reporting Person were acquired in connection with the transactions described in Item 3 above.

The Reporting Person has made no plans or proposals which would be related to or would result in any of the events or matters described in part (a) through (j) of Item 4 above.

**Item 5. Interest in Securities of the Issuer**

**(a)**
The Reporting Person beneficially owns 1,833,750 shares of common stock, which includes 1,366,400 shares of common stock and 467,350 shares of common stock that the Reporting Person has the right to acquire within sixty (60) days through the exercise of vested stock options. Such 1,833,750 shares represent 16.8% of the Issuer's outstanding common stock, based on 10,442,438 shares of common stock of the Issuer outstanding as of March 3, 2026.

**(b)**
See Rows 7-10 of the cover page.

**(c)**
See Item 3 above.

**Item 6. Contracts, Arrangements, Understandings or Relationships With Respect to Securities of the Issuer.**

None.

### SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

**Reporting Person:** Jonathan M Cohen

**Signature:** /s/ Jonathan Cohen

**Name/Title:** Jonathan Cohen

**Date:** 03/10/2026